Not Signed In - Lux Biosciences Receives Orphan Drug Designation From The FDA For Two Ophthalmic Products
Tue, 16 Jan 2007 08:00 AM EST
... Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to two of the company's investigational therapeutics. [click link for full article] ...
Related Topics
- Drug Safety
- Polymyxin B, Bacitracin, and Neomycin Ophthalmic Ointment
- Prescription Drugs
- Drug Side Effects
- Trimethoprim and Polymyxin Ophthalmic
- Drug Abuse
- Drug Information
- Prescription Drug Abuse
- Diclofenac Ophthalmic
- Prescription Drugs Abuse
- Dexamethasone Ophthalmic
- Gatifloxacin Ophthalmic
- Cyclosporine Ophthalmic
- Tacrolimus ointment
- Diet Products
- Tobramycin and Dexamethasone Ophthalmic
- Weight Loss Products
- Tysabri
- Hydrocortisone, Neomycin, and Polymyxin Ophthalmic Drops
- Ofloxacin Ophthalmic Drops
email this page
print this page
bookmark this page
feedback on this page
